Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 8/20 | 0.40 |
| ▸ | HTR2C | P28335 | 8/20 | 0.40 |
| ▸ | HTR2B | P41595 | 6/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25523284 | 0.85 | HTR2B (0.39) | HTR2AHTR2CHTR2BADRA2AAKR1B1 | |
| SCHEMBL25860608 | 0.81 | AKR1B1 (0.42) | AKR1B1ALKKDM4C | |
| SCHEMBL25526152 | 0.73 | ALK (0.33) | ADRA2AAKR1B1ALKKDM4C | |
| SCHEMBL25854637 | 0.73 | CYP3A4 (0.35) | ADRA2AAKR1B1ALK | |
| SCHEMBL25854099 | 0.73 | ALK (0.33) | HTR2AHTR2CHTR2BSLC6A4ADRA2A | |
| SCHEMBL31485644 | 0.72 | ADRA2A (0.31) | ADRA2A | |
| SCHEMBL25526154 | 0.72 | ADRA2A (0.31) | ADRA2A | |
| Hydrochloric Acid SCHEMBL31485620 | 0.71 | HTR2A (0.31) | HTR2AHTR2CHTR2BADRA2A | |
| SCHEMBL29920682 | 0.69 | CA2 (0.38) | HTR2CHTR2BSLC6A2 | |
| SCHEMBL29920290 | 0.69 | CA2 (0.38) | HTR2CHTR2BSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227437-A1 | IMMUNOMODULATOR | HITGEN INC (CN) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227437-A1 | IMMUNOMODULATOR | IL17A, IL2, IL2RA | HTR2A 3768/4885HTR2C 4060/4885HTR2B 4123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.